You can buy or sell TCON and other stocks, options, ETFs, and crypto commission-free!
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. Read More The company was founded in October 2004 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carc...
Simply Wall StMar 2
How Much Of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Do Insiders Own?
A look at the shareholders of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your portfolio.’ TRACON Pharmaceuticals is not a large company by global standards. It has a market capit...
Seeking AlphaFeb 28
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q4 2018 Results - Earnings Call Transcript
TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Director, Controller Conference Call Participants Maury Raycroft - Jefferies Jake Colby - BTIG Nick Abbot - Wells Fargo Operator Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2018 Earnings Conference Call. At this time, all callers are in a listen-only ...
Expected May 8, After Hours